Deborah Kochevar - Charles River Independent Director
| CRL Stock | USD 199.59 1.84 0.93% |
Director
Dr. Deborah Turner Kochevar, D.V.M., Ph.D. is an Independent Director of Charles River Laboratories International Inc. She is Dean of the Cummings School of Veterinary Medicine at Tufts University since 2006. Dr. Kochevar will assume provost ad interim duties at Tufts University in April 2018. Previously, Dr. Kochevar was a longtime faculty member and administrator at the College of Veterinary Medicine and Biomedical Sciences, Texas AM University, where she held the Wiley Chair of Veterinary Medical Education. Dr. Kochevar is a pastpresident of the Association of American Veterinary Medical Colleges and American College of Veterinary Clinical Pharmacology. Dr. Kochevar is active in the American Veterinary Medical Association, having chaired its Council on Education and the Educational Commission for Foreign Veterinary Graduates. Dr. Kochevar was a director since October 2008. Dr. Kochevar was selected to the Board in recognition of her distinct perspective as a highly distinguished academic and educator in the life sciences. As a boarded diplomate of the American College of Veterinary Clinical Pharmacology, with a Ph.D. in cell and molecular biology combined with a D.V.M. degree, and with a deep knowledge base of comparative medicine and complex animal models, Dr. Kochevar training and experience is particularly suited to understanding and providing insights into the veterinary medical, contract research and drug development support activities that we conduct. Dr. Kochevar also provides the Board with current industry and scientific insights through her ongoing involvement in a broad array of biomedical professional and trade organizations. since 2008.
| Age | 64 |
| Tenure | 16 years |
| Address | 251 Ballardvale Street, Wilmington, MA, United States, 01887 |
| Phone | 781 222 6000 |
| Web | https://www.criver.com |
Charles River Management Efficiency
The company has Return on Asset of 0.0487 % which means that on every $100 spent on assets, it made $0.0487 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1192 %, implying that it generated $0.1192 on every 100 dollars invested. Charles River's management efficiency ratios could be used to measure how well Charles River manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Charles River's Return On Capital Employed is quite stable compared to the past year. Return On Assets is expected to rise to 0.06 this year, although the value of Return On Tangible Assets will most likely fall to 0.12. At this time, Charles River's Deferred Long Term Asset Charges is quite stable compared to the past year. Return On Assets is expected to rise to 0.06 this year, although the value of Other Assets will most likely fall to 1,092.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| James Fasano | IQVIA Holdings | 50 | |
| Robert Williams | Laboratory of | 72 | |
| Christopher Kuebler | Waters | 66 | |
| Linda Baddour | Waters | 62 | |
| Laurie Glimcher | Waters | 66 | |
| Kerrii Anderson | Laboratory of | 63 | |
| Ronald Rittenmeyer | IQVIA Holdings | 73 | |
| Michael Berendt | Waters | 71 | |
| Colleen Goggins | IQVIA Holdings | 66 | |
| George Scangos | Agilent Technologies | 72 | |
| Elisha Finney | Mettler Toledo International | 59 | |
| Hans Bishop | Agilent Technologies | 56 | |
| Todd Sisitsky | IQVIA Holdings | 49 | |
| Mala Anand | Agilent Technologies | 53 | |
| Francis deSouza | Illumina | 53 | |
| Dow Wilson | Agilent Technologies | 61 | |
| Daniel Podolsky | Agilent Technologies | 67 | |
| Heidi Kunz | Agilent Technologies | 66 | |
| Richelle Parham | Laboratory of | 53 | |
| Thomas Salice | Waters | 61 | |
| Richard Francis | Mettler Toledo International | 52 | |
Management Performance
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0487 |
Charles River Labora Leadership Team
Elected by the shareholders, the Charles River's board of directors comprises two types of representatives: Charles River inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Charles. The board's role is to monitor Charles River's management team and ensure that shareholders' interests are well served. Charles River's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Charles River's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph JD, Corporate Strategy | ||
| Robert Bertolini, Independent Director | ||
| Birgit Girshick, Corporate Executive Vice President, Global Discovery and Safety Assessment, Biologics and Avian | ||
| James Foster, Chairman of the Board, President, Chief Executive Officer | ||
| Joseph LaPlume, Corporate Executive Vice President - Corporate Development and Strategy | ||
| Mark Mintz, Corporate Officer | ||
| Michael Knell, Corporate Senior Vice President Chief Accounting Officer | ||
| George Milne, Lead Independent Director | ||
| George Llado, Independent Director | ||
| Nancy Andrews, Independent Director | ||
| Victoria Creamer, Corporate Senior Vice President Chief People Officer. | ||
| JeanPaul Mangeolle, Independent Director | ||
| Gina Mullane, Chief VP | ||
| Richard Wallman, Independent Director | ||
| Pr Frearson, Corporate Officer | ||
| David Smith, Chief Financial Officer, Corporate Executive Vice President | ||
| James JD, President CEO | ||
| Matthew Daniel, General VP | ||
| Martin Mackay, Independent Director | ||
| Virginia Wilson, Independent Director | ||
| Flavia Pease, Corporate Executive Vice President | ||
| Amy Cianciaruso, Corporate Officer | ||
| Matthew JD, General VP | ||
| Todd Spencer, Corporate Relations | ||
| Deborah Kochevar, Independent Director | ||
| William Barbo, Corporate Executive Vice President and Chief Commercial Officer | ||
| Stephen Chubb, Independent Director | ||
| Richard Reese, Independent Director | ||
| George Massaro, Independent Director |
Charles Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Charles River a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0487 | ||||
| Profit Margin | 0.10 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 12.66 B | ||||
| Shares Outstanding | 51.14 M | ||||
| Shares Owned By Insiders | 0.92 % | ||||
| Shares Owned By Institutions | 99.08 % | ||||
| Number Of Shares Shorted | 1.93 M | ||||
| Price To Earning | 33.74 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Charles River Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Charles River. If investors know Charles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Charles River listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.21) | Earnings Share 8.01 | Revenue Per Share 78.97 | Quarterly Revenue Growth (0.02) | Return On Assets 0.0487 |
The market value of Charles River Labora is measured differently than its book value, which is the value of Charles that is recorded on the company's balance sheet. Investors also form their own opinion of Charles River's value that differs from its market value or its book value, called intrinsic value, which is Charles River's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Charles River's market value can be influenced by many factors that don't directly affect Charles River's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Charles River's value and its price as these two are different measures arrived at by different means. Investors typically determine if Charles River is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Charles River's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.